donepezil has been researched along with Adverse Drug Event in 12 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Excerpt | Relevance | Reference |
---|---|---|
" Symptoms, interventions, and treatment-related adverse events addressed in this issue are management of Alzheimer's agitation with donepezil; needle-free lidocaine powder for minor painful procedures; psychostimulants in depression; anticoagulation for cancer-related venous thromboembolism; effect of waiting for acute pain treatment on risk of chronic pain; and an update on severe cutaneous reactions associated with medications." | 4.85 | Pain and palliative care pharmacotherapy literature summaries and analyses. ( Abernethy, AP; Farrell, TW, 2009) |
"Data was based on the Japanese Adverse Drug Event Report (JADER) database." | 1.91 | Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database. ( Ando, A; Enomoto, H; Kose, E; Tate, N; Yamamoto, T; Yasuno, N, 2023) |
" Here, we report an extrapyramidal adverse reaction to donepezil in an elderly patient with AD." | 1.56 | Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report. ( Li, HC; Luo, KX; Wang, JS; Wang, QX, 2020) |
"To describe ChEI related ADRs in Alzheimer's disease (donepezil, rivastigmine, and galantamine) and characterize their seriousness as reported by national pharmacovigilance systems to VigiBase, a World Health Organization International Drug Monitoring Program database, between 1998 and 2013." | 1.42 | Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase. ( Berkers, M; Carmichael, PH; Egberts, T; Kröger, E; Laroche, ML; Mouls, M; Souverein, P; van Marum, R; Wilchesky, M, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (16.67) | 29.6817 |
2010's | 7 (58.33) | 24.3611 |
2020's | 3 (25.00) | 2.80 |
Authors | Studies |
---|---|
Dawson, S | 1 |
Stahl, S | 1 |
Paul, N | 1 |
Barber, J | 1 |
Kenna, JG | 1 |
Liu, Z | 1 |
Shi, Q | 1 |
Ding, D | 1 |
Kelly, R | 1 |
Fang, H | 1 |
Tong, W | 1 |
Sakatis, MZ | 1 |
Reese, MJ | 1 |
Harrell, AW | 1 |
Taylor, MA | 1 |
Baines, IA | 1 |
Chen, L | 1 |
Bloomer, JC | 1 |
Yang, EY | 1 |
Ellens, HM | 1 |
Ambroso, JL | 1 |
Lovatt, CA | 1 |
Ayrton, AD | 1 |
Clarke, SE | 1 |
Morgan, RE | 1 |
van Staden, CJ | 1 |
Chen, Y | 1 |
Kalyanaraman, N | 1 |
Kalanzi, J | 1 |
Dunn, RT | 1 |
Afshari, CA | 1 |
Hamadeh, HK | 1 |
Kose, E | 1 |
Yamamoto, T | 1 |
Tate, N | 1 |
Ando, A | 1 |
Enomoto, H | 1 |
Yasuno, N | 1 |
Adelman, M | 1 |
Louis, L | 1 |
Li, HC | 1 |
Luo, KX | 1 |
Wang, JS | 1 |
Wang, QX | 1 |
Kröger, E | 1 |
Mouls, M | 1 |
Wilchesky, M | 1 |
Berkers, M | 1 |
Carmichael, PH | 1 |
van Marum, R | 1 |
Souverein, P | 1 |
Egberts, T | 1 |
Laroche, ML | 1 |
Campbell, NL | 1 |
Perkins, AJ | 1 |
Gao, S | 1 |
Skaar, TC | 1 |
Li, L | 1 |
Hendrie, HC | 1 |
Fowler, N | 1 |
Callahan, CM | 1 |
Boustani, MA | 1 |
Abernethy, AP | 1 |
Farrell, TW | 1 |
Gold, M | 1 |
Alderton, C | 1 |
Zvartau-Hind, M | 1 |
Egginton, S | 1 |
Saunders, AM | 1 |
Irizarry, M | 1 |
Craft, S | 1 |
Landreth, G | 1 |
Linnamägi, U | 1 |
Sawchak, S | 1 |
Cassels, A | 1 |
Hughes, MA | 1 |
Cole, C | 1 |
Mintzes, B | 1 |
Lexchin, J | 1 |
McCormack, JP | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs[NCT01362686] | 200 participants (Actual) | Interventional | 2011-04-30 | Terminated (stopped due to Low study accrual caused the study to be ended early.) | |||
Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial[NCT02409238] | Phase 4 | 105 participants (Actual) | Interventional | 2015-03-11 | Terminated (stopped due to "Limits of grant funding reached~A/Prof Ng Tze Pin (P.I. & holder of NMRC Grant (CIRG12may033) funding this study) retired in Aug 2022.~Resignations of staff and collaborators especially over the 1st 2 years of the COVID-19 pandemic") | ||
A 24-week, Double-blind, Double-dummy, Randomized, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets), Donepezil, and Placebo as Monotherapy on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects[NCT00428090] | Phase 3 | 862 participants (Actual) | Interventional | 2007-02-27 | Completed | ||
An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.[NCT00550420] | Phase 3 | 331 participants (Actual) | Interventional | 2007-10-01 | Terminated (stopped due to Based on preliminary parent study results) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
We are not seeking to establish efficacy of these three medications for the indication of Alzheimer's disease. Each of these medications already has FDA-approval for Alzheimer's. The primary outcome measure is the discontinuation rate among the three medications. Based on previous systematic reviews, these rates are reportedly in the range of 30% by 12 weeks compared with placebo. We will determine the approximate date of discontinuation by self-reports from the caregiver through the telephone-based interview at 6, 12, and 18 weeks. (NCT01362686)
Timeframe: 6, 12, and 18 week interviews from enrollment
Intervention | participants (Number) |
---|---|
Donepezil | 26 |
Galantamine | 35 |
Rivastigmine | 37 |
The current HABC-Monitor includes 30 items covering four clinically relevant domains of dementia, ie, cognitive, functional, behavioral, and psychological symptoms, and caregiver quality of life. For brevity and practical use in the clinical setting, each item on the four scales was designed to have the same item response options consisting of four categories that use the frequency of the target problem in the past 2 weeks. The HABC- Monitor took approximately 6 minutes to complete. The scores of the four scales are summed to create the total scores which were used in this analysis.The higher the total score, the higher the level of self reported caregiver burden. The minimum score is 0 and the maximum score is 90. (NCT01362686)
Timeframe: baseline, 6, 12, and 18 week interviews
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Baseline HABC | 6 Week HABC | 12 Week HABC | 18 Week HABC | |
Donepezil | 18.76 | 18.61 | 16.04 | 16.90 |
Galantamine | 18.34 | 19.16 | 18.00 | 19.92 |
Rivastigmine | 16.61 | 16.43 | 13.63 | 15.80 |
The NPI is based on a structured interview administered to an informal caregiver and has been adopted by the Alzheimer's Disease Cooperative Studies Group to obtain information on the presence of psychopathology in behavioral areas including delusions, apathy, hallucinations, disinhibition, agitation, depression, aberrant motor behavior, anxiety, night-time behavior, and euphoria.9 For each of 12 symptoms, if the caregiver reports the presence of psychopathology, a frequency and severity score are multiplied to yield a possible item score range of 0-12, and a possible total score range of 0-144. The NPI can be used to assess changes in the patient's behavior over the past month. The NPI also assesses the level of caregiver distress attributable to each of the 12 patient behaviors, with a possible total caregiver distress score range of 0-60. Higher scores indicate higher severity of psychopathology and caregiver disress. The NPI has excellent reliability and validity. (NCT01362686)
Timeframe: Baseline, 6, 12, 18 week interviews from enrollment
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
6 WeekNPI Patient | 6 Week NPI Caregiver | 12 Week NPI Patient | 12 Week NPI Caregiver | 18 Week NPI Patient | 18 Week NPI Caregiver | |
Donepezil | 12.71 | 5.94 | 9.62 | 5.66 | 9.06 | 5.56 |
Galantamine | 9.42 | 4.40 | 8.40 | 4.33 | 10.67 | 6.22 |
Rivastigmine | 8.63 | 3.91 | 5.24 | 2.22 | 7.26 | 2.89 |
The blood sample was collected for assessments of HbA1c levels at Baseline and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and W24
Intervention | Percentage (%) (Least Squares Mean) |
---|---|
Placebo | 0.1 |
RSG XR 2 mg | 0.2 |
RSG XR 8 mg | 0.1 |
Donepezil 10 mg | 0.1 |
Triplicate 12-lead ECG measures was obtained digitally, approximately one minute apart after the par. had rested in the supine position in a quiet room (no TV, minimal talking) for at least 10 minutes. Conduction intervals from the 12-lead ECGs were manually read and confirmed by an external cardiologist/vendor. The ECG HR of Central Cardiologist reported. The assessments was performed at Baseline and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Screening/Visit 1/W-6. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Beats per minute (Mean) |
---|---|
Placebo | 2.1 |
RSG XR 2 mg | -2.8 |
RSG XR 8 mg | -0.3 |
Donepezil 10 mg | -4.7 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Items were evaluated by tests and clinician ratings on a 5-point scale. Scores ranged from 0-70 with higher scores indicates more dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline is defined as value at W0. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
Intervention | Score on a scale (Least Squares Mean) |
---|---|
Placebo | 1.5 |
RSG XR 2 mg | 0.3 |
RSG XR 8 mg | 0.7 |
Donepezil 10 mg | -0.1 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Items were evaluated by tests and clinician ratings on a 5-point scale. Scores ranged from 0-70 with higher scores indicates more dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline is defined as value at W0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
Intervention | Score on a scale (Least Squares Mean) |
---|---|
Placebo | 1.6 |
RSG XR 2 mg | -0.2 |
RSG XR 8 mg | 0.6 |
Donepezil 10 mg | 0.9 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Items were evaluated by tests and clinician ratings on a 5-point scale. Scores ranged from 0-70 with higher scores indicates more dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline is defined as value at W0. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
Intervention | Score on a scale (Least Squares Mean) |
---|---|
Placebo | 2.0 |
RSG XR 2 mg | 1.2 |
RSG XR 8 mg | 1.2 |
Donepezil 10 mg | 0.6 |
The CIBIC+ assessment comprised of a 7-point rating of severity (at baseline) and change (at indicated time points). It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; higher score means greater dysfunction. It was based on interviews with the par. and caregiver by an independent rater. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
Intervention | Score on a scale (Least Squares Mean) |
---|---|
Placebo | 4.3 |
RSG XR 2 mg | 4.3 |
RSG XR 8 mg | 4.1 |
Donepezil 10 mg | 3.8 |
The CIBIC+ assessment comprised of a 7-point rating of severity (at baseline) and change (at indicated time points). It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; higher score means greater dysfunction. It was based on interviews with the par. and caregiver by an independent rater. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
Intervention | Score on a scale (Least Squares Mean) |
---|---|
Placebo | 4.2 |
RSG XR 2 mg | 4.2 |
RSG XR 8 mg | 4.1 |
Donepezil 10 mg | 3.9 |
The CIBIC+ assessment comprised of a 7-point rating of severity (at baseline) and change (at indicated time points). It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; higher score means greater dysfunction. It was based on interviews with the par. and caregiver by an independent rater. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. Estimated value was calculated by Active treatment minus Placebo. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the three genetic subgroups. There was no adjustment for the donepezil versus placebo comparisons, which were included to assess the sensitivity of the trial to detect a treatment effect. (NCT00428090)
Timeframe: Baseline (W0) and W24
Intervention | Score on a scale (Least Squares Mean) |
---|---|
Placebo | 4.3 |
RSG XR 2 mg | 4.3 |
RSG XR 8 mg | 4.2 |
Donepezil 10 mg | 3.8 |
The MMSE consists of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. The scale is completed by the investigator, based on the performance of the par. and takes approximately 5 to 10 minutes to administer. The assessments was performed at Baseline and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived (NCT00428090)
Timeframe: Baseline (W0) and W24
Intervention | Score on a scale (Least Squares Mean) |
---|---|
Placebo | -0.5 |
RSG XR 2 mg | -0.6 |
RSG XR 8 mg | -0.7 |
Donepezil 10 mg | 0.4 |
Triplicate 12-lead ECG measures was obtained digitally, approximately one minute apart after the par. had rested in the supine position in a quiet room (no TV, minimal talking) for at least 10 minutes. Conduction intervals from the 12-lead ECGs were manually read and confirmed by an external cardiologist/vendor. The ECG parameters includes PR interval, QRS duration, QT - uncorrected interval, QTc Bazett (QTcB), QTc Fridericia (QTcF) and RR interval of Central Cardiologist are reported. The assessments was performed at Baseline and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Screening/Visit 1/W-6. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | milliseconds (MSEC) (Mean) | |||||
---|---|---|---|---|---|---|
PR Interval, n=16,11, 14, 4 | QRS Duration, n=17, 11, 14, 5 | QT Interval, n=17, 11, 14, 5 | QTcB, n=17, 11, 14, 5 | QTcF, n=17, 11, 14, 5 | RR Interval | |
Donepezil 10 mg | -5.5 | 0.9 | 15.9 | -0.2 | 4.9 | 76.5 |
Placebo | 2.2 | 1.1 | 5.3 | 10.2 | 8.1 | -12.3 |
RSG XR 2 mg | 6.9 | 0.7 | 15.6 | 7.1 | 10.0 | 43.8 |
RSG XR 8 mg | 6.0 | 3.6 | 19.8 | 20.0 | 20.1 | -0.5 |
The ACQLI was an assessment of caregiver quality of life. This instrument consists of 30 questions exploring various aspects of carer's quality of life. Each of the questions had a two point response and the 30 questions were summed to provide a total score. Items are assumed to be unidimensional (i.e., represent a single variable) and are scored 0/1 (false/true) before summation into a total score with a 0-30 range. To ease comparisons between scales, ACQLI scores were transformed to range between 0-100 (100: worse). The assessments was performed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Score on a scale (Least Squares Mean) | |
---|---|---|
ACQLI, W12, n=141, 148, 137, 60 | ACQLI, W24, n=128, 132, 126, 54 | |
Donepezil 10 mg | 0.5 | -0.0 |
Placebo | 0.5 | 0.6 |
RSG XR 2 mg | -0.6 | -0.2 |
RSG XR 8 mg | -0.1 | 0.0 |
Body weight will be measured at all visits, without shoes and wearing light clothing. The assessments was performed at Baseline, W4, W8, W12, W16, and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Kilogram (Kg) (Mean) | ||||
---|---|---|---|---|---|
Week 4, n=160, 161, 153, 79 | Week 8, n=150, 157, 147, 66 | Week 12, n=143, 149, 136, 61 | Week 16, n=143, 146, 132, 61 | Week 24, 133, 132, 125, 55 | |
Donepezil 10 mg | -0.1 | -0.4 | -0.9 | -1.0 | -0.8 |
Placebo | 0.1 | -0.0 | 0.0 | -0.0 | -0.3 |
RSG XR 2 mg | 0.4 | 0.5 | 0.6 | 0.7 | 0.8 |
RSG XR 8 mg | 0.3 | 0.8 | 0.9 | 1.1 | 0.8 |
Hematology parameters were assessed at Baseline, W4, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Baseline (W0) and Up to W24
Intervention | Percentage of red blood cells in blood (Mean) | ||
---|---|---|---|
Week 4, n=152, 152, 138, 76 | Week 12, n=132, 142, 132, 60 | Week 24, n=128, 124, 115, 54 | |
Donepezil 10 mg | -0.0024 | -0.0055 | -0.0001 |
Placebo | -0.0011 | -0.0007 | -0.0010 |
RSG XR 2 mg | -0.0088 | -0.0152 | -0.0123 |
RSG XR 8 mg | -0.0125 | -0.0316 | -0.0326 |
Hematology parameters were assessed at Baseline, W4, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Grams per liter (G/L) (Mean) | ||
---|---|---|---|
Week 4, n=152, 152, 138, 76 | Week 12, n=132, 142, 132, 60 | Week 24, n=128, 124, 115, 54 | |
Donepezil 10 mg | -0.4 | -0.6 | 0.2 |
Placebo | 0.1 | -0.2 | -1.3 |
RSG XR 2 mg | -2.8 | -4.5 | -4.2 |
RSG XR 8 mg | -3.9 | -10.5 | -11.9 |
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a 5-point scale. Scores ranged from 0-70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline is defined as value at W0. Endpoint treatment differences were adjusted to take account of missing data. It was evaluated at Baseline, W8, W16 and W24. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Score on a scale (Least Squares Mean) | ||
---|---|---|---|
ADAS-Cog, W8, n=153, 155,147,67 | ADAS-Cog, W16, n=143,145,132,62 | ADAS-Cog, W24, n=131, 130,125,156 | |
Donepezil 10 mg | -0.3 | -1.1 | 0.6 |
Placebo | 0.4 | 0.5 | 2.0 |
RSG XR 2 mg | -0.5 | 0.6 | 1.2 |
RSG XR 8 mg | 0.5 | 1.3 | 1.2 |
The CIBIC+ assessment comprised of a 7-point rating of severity (at baseline) and change (at indicated time points). It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; higher score means more dysfunction. The scale was based on interviews with the par. and caregiver and was completed by an independent rater. It required separate structured 15-20 minute interviews with the par. and caregiver. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. It was evaluated at Baseline, W8, W16 and W24. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Score on a scale (Least Squares Mean) | ||
---|---|---|---|
CIBIC+, W8, n=150, 156,147,67 | CIBIC+, W16, n=144,145,127,61 | CIBIC+, W24, n=131,133, 127, 56 | |
Donepezil 10 mg | 3.9 | 3.8 | 3.8 |
Placebo | 4.1 | 4.2 | 4.3 |
RSG XR 2 mg | 3.9 | 4.0 | 4.3 |
RSG XR 8 mg | 4.1 | 4.1 | 4.2 |
The DAD, assessed the ability of a par. to execute basic and instrumental activities of daily living (ADL) and leisure activities. The scale consists of 40 questions assessing basic and instrumental ADLs. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item was scored as yes: 1, no: 0 and N/A: not applicable. Higher scores indicate less disability with a score of 100 indicating no disability and 0 indicating no functional ability. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. The percentage score was calculated as (DAD total score/total number of applicable items) multiplied by 100. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Score on a scale (Least Squares Mean) | ||
---|---|---|---|
DAD, W8, n=147,152, 144, 65 | DAD, W16, n=141,143,131,59 | DAD, W24, n=129,133,127,55 | |
Donepezil 10 mg | 0.5 | 1.1 | -0.2 |
Placebo | -0.8 | -2.6 | -3.7 |
RSG XR 2 mg | -0.6 | -1.7 | -2.4 |
RSG XR 8 mg | -0.3 | -1.7 | -3.8 |
The EQ-5D Proxy is a 2 part scale used to assess the quality of life and utility benefit. The data for Part 2 is presented. It is a the visual analogue scale Thermometer which assessed caregiver's impression of par. overall health. The Thermometer has endpoints of 100 (best imaginable health state) and 0 (worst imaginable health state). EQ-5D Proxy assessments was performed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Score on a scale (Least Squares Mean) | |
---|---|---|
EQ-5D Proxy Thermometer, W12, n=141, 146, 135, 62 | EQ-5D Proxy Thermometer, W24, n=128, 130, 126, 55 | |
Donepezil 10 mg | -2.6 | 1.5 |
Placebo | 1.4 | 1.9 |
RSG XR 2 mg | 0.3 | -0.7 |
RSG XR 8 mg | 1.7 | 0.2 |
The EQ-5D Proxy was a 2 part scale used to assess the quality of life and utility benefit. The data for Part 1 is presented. It is a 5 dimensional Health State Classification. Caregivers were asked to respond as they feel the par. would on dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Answers to each question were recorded on a 3-point scale which indicates the level of impairment (level 1= no problem; level 2=some or moderate problem(s) and level 3=unable, or extreme problem with higher scores indicating greater dysfunction. EQ-5D Proxy assessments was performed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Score on a scale (Least Squares Mean) | |
---|---|---|
EQ-5D Proxy Utility, W12, n=141,146, 135, 62 | EQ-5D Proxy Utility, W24, n=128, 130, 125, 55 | |
Donepezil 10 mg | 0.01 | 0.00 |
Placebo | -0.02 | -0.02 |
RSG XR 2 mg | 0.00 | 0.02 |
RSG XR 8 mg | 0.01 | -0.02 |
"The NPI assessed behavioral disturbances comprises 10 dimensions: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressiveness and agitation, irritability, anxiety and aberrant motor activity. The par. caregiver asked about behavior in the par. If Yes, the informant then rates both the severity on a 3-point scale, 1: mild to 3: severe (total range: 0-36) and the frequency using a 4-point scale, 1: occasionally to 4: very frequently. The total domain score was frequency × severity. The distress was scored on 5-point scale, 0: no distress to 5 - very severe or extreme. A total NPI score can be calculated by adding all domain scores together; NPI total score: from 0-144 and NPI distress score: from 0-60, all with higher scores indicating more severe behavioral disturbance. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0." (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Score on a scale (Least Squares Mean) | ||
---|---|---|---|
NPI, W8, n=146,151,144,65 | NPI, W16, n=139,142,131,59 | NPI, W24, n=129,133,127,55 | |
Donepezil 10 mg | -0.1 | 0.5 | -0.6 |
Placebo | 0.2 | -0.1 | 1.2 |
RSG XR 2 mg | 0.1 | -0.0 | 1.6 |
RSG XR 8 mg | 0.5 | -0.1 | 1.1 |
Change from Baseline in short term memory assessment score was assessed from a combined analysis of items 1 (word recall task) and 7 (word recognition task) of ADAS-Cog scale. Word recall task consist of the participants score was the mean number of words not recalled on three trials (maximum score 10) and word recognition task, to score this item the number of incorrect responses was counted (maximum error score was 12). Higher score indicating greater dysfunction. Total score is sum of individual score. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Score on a scale (Least Squares Mean) | ||
---|---|---|---|
ADAS-Cog Q1 plus Q7, W8, n=152,155,146,67 | ADAS-Cog Q1 plus Q7, W16, n=143,143,130,62 | ADAS-Cog Q1 plus Q7, W24, n=131,128,123,56 | |
Donepezil 10 mg | -0.4 | -0.6 | 0.2 |
Placebo | 0.1 | 0.1 | 0.7 |
RSG XR 2 mg | -0.1 | 0.6 | 0.3 |
RSG XR 8 mg | 0.5 | 0.8 | 0.6 |
HbA1c assessment was performed par. with type 2 diabetes mellitus or HbA1c >=6.5% at Screening only. HbA1c levels were assessed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Percentage (Mean) | |
---|---|---|
Week 12, n=48, 46, 38, 22 | Week 24, n=123, 120, 117, 52 | |
Donepezil 10 mg | -0.2 | 0.0 |
Placebo | -0.1 | 0.1 |
RSG XR 2 mg | 0.2 | 0.2 |
RSG XR 8 mg | 0.1 | 0.1 |
Clinical chemistry parameters were identified as of PCC (H, L), if values were out of RR: Alanine aminotransferase (ALT, none-120 [250% upper limit of RR, ULRR]), Albumin (0.75-2), Aspartate aminotransferase (AST,none-105 (3-64y), 137.5 (65+y), >250%ULRR), Alkaline phosphatase (ALP,none-312.5 (20+y), >250%ULRR), blood urea nitrogen (BUN)/Creatinine ratio (none-1.25), BUN (none-11), Chloride (80-115), Calcium (0.75-1.25), Carbon dioxide (CO2, 15-40) content, Creatinine (22, <50% lower limit of RR [LLRR]-155, >125%ULRR), Creatine phosphokinase (CPK, none-1.25), Gamma glutamyl transferase (GGT,none-2.5), Glucose (3.6-7.8), High density lipoprotein (HDL,0.65-none), Lactate dehydrogenase (LDH,none-1.25), Low density lipoprotein (LDL,none-2), Magnesium (0.5-2), Potassium (3-5.5), Phosphorus inorganic (0.5-1.5), Sodium (130-150), Total protein (0.8-1.5), Total cholesterol (none-1.25), Total bilirubin (none-1.95), Triglycerides (none-9). Data for Creatinine clearance not reported. (NCT00428090)
Timeframe: Up to W24
Intervention | Participants (Number) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALT H, n=156, 162, 151, 77 | AST H, n=156, 162, 151, 77 | BUN/Creatinine ratio H, n=156, 162, 151, 77 | Cholesterol H, n=141, 148, 137, 62 | Creatinine H, n=156, 162, 151, 77 | CPK H, n=156, 162, 151, 77 | GGT H, n=156, 162, 151, 77 | Glucose H, n=156, 162, 151, 77 | Glucose L, n=156, 162, 151, 77 | LDL H, n=141, 147, 136, 62 | Phosphorus L, n=156, 162, 151, 77 | Potassium H, n=156, 162, 150, 77 | Sodium H, n=156, 162, 151, 77 | Sodium L, n=156, 162, 151, 77 | BUN H, n=156, 162, 151, 77 | Total Bilirubin H, n=156, 162, 151, 77 | |
Donepezil 10 mg | 0 | 0 | 9 | 1 | 3 | 5 | 1 | 8 | 1 | 10 | 0 | 2 | 1 | 2 | 5 | 0 |
Placebo | 2 | 2 | 8 | 7 | 5 | 5 | 2 | 12 | 3 | 36 | 0 | 4 | 0 | 0 | 7 | 0 |
RSG XR 2 mg | 0 | 0 | 8 | 17 | 1 | 13 | 1 | 19 | 5 | 51 | 0 | 2 | 0 | 0 | 5 | 1 |
RSG XR 8 mg | 0 | 0 | 19 | 29 | 4 | 11 | 0 | 9 | 4 | 55 | 1 | 2 | 0 | 1 | 12 | 0 |
Haematology parameters were identified as of PCC (high [H], low [L]), if the values were out of the reference range (RR). The range for parameters was: platelet (100AV-500AV), red blood cell (RBC, 0.8-1.2), hemoglobin (L: female [F]:10, male [M]:11; H: F:16.5-AV, M:18), hematocrit (0.8-1.2), white blood cell (WBC, 3-15), neutrophils (0.75-1.5), lymphocytes (0.75-1.5), monocytes (0.75-2), eosinophils (none-2), basophils (none-2), mean corpuscle volume (MCV, 0.8-1.2), mean corpuscular hemoglobin (MCH, 0.8-1.2), mean corpuscular hemoglobin concentration (MCHC, 0.8-1.2), red cell distribution width (RDW, 0.8-1.2). Data for mean platelet volume (reference range not established) not reported (NCT00428090)
Timeframe: Up to W24
Intervention | Participants (Number) | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eosinophils H, n=156, 161, 151, 72 | Hematocrit H, n=157, 161,151, 76 | Hematocrit L, n=157, 161,151, 76 | Hemoglobin H, n=157, 161,151, 76 | Hemoglobin L, n=157, 161,151, 76 | Lymphocytes L, n=156, 161,151, 76 | MCH H, n=157, 161,151, 76 | MCH L, n=157, 161,151, 76 | MCV L, n=156, 161,151, 76 | Monocytes H, n=156, 161,151, 76 | Monocytes L, n=156, 161,151, 76 | Platelet H, n=157, 160,150, 76 | Platelet L, n=157, 160,150, 76 | RDW H, n=157, 161,151, 76 | RBC L, n=157, 161,151, 76 | Total neutrophil H, n=156, 161, 151, 76 | Total neutrophil L, n=156, 161, 151, 76 | WBC H, n=157, 161,151, 76 | WBC L, n=157, 161,151, 76 | |
Donepezil 10 mg | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 4 | 0 | 0 | 1 | 1 | 1 | 3 | 1 | 0 |
Placebo | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 9 | 1 | 2 | 4 | 0 | 0 | 2 | 0 | 4 |
RSG XR 2 mg | 0 | 1 | 0 | 2 | 3 | 2 | 0 | 1 | 0 | 0 | 10 | 0 | 1 | 6 | 1 | 0 | 5 | 0 | 4 |
RSG XR 8 mg | 1 | 0 | 1 | 0 | 8 | 2 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 10 | 1 | 1 | 7 | 1 | 7 |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE included significant or unexpected worsening or exacerbation of the condition/indication under study, exacerbation of a chronic or intermittent pre-existing condition, new conditions detected or diagnosed, signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational product or a concurrent medication. Number of participants with any AE and as per severity were reported. Refer to the general AE/SAE module for a list of AEs and SAEs. (NCT00428090)
Timeframe: Up to W24
Intervention | Participants (Number) | |||
---|---|---|---|---|
Any AE | Mild AE | Moderate AE | Severe AE | |
Donepezil 10 mg | 42 | 22 | 15 | 5 |
Placebo | 62 | 32 | 25 | 5 |
RSG XR 2 mg | 60 | 35 | 22 | 3 |
RSG XR 8 mg | 69 | 37 | 30 | 2 |
SBP, DBP and HR of par. were recorded in sitting posture as vital signs, while body weight was measured without shoes and wearing light clothing at each visit. The blood pressure (BP) and HR values were identified as of PCC if the vales were out of the reference range (for SBP, 90 to 140 millimeters of mercury (mmHg), DBP, 50 to 90 mmHg, and HR >100 or <50 beats per minute [bpm]) or meet a change from Baseline criterion. For SBP it was increase from Baseline (high) if increased by more than or equal to (>=) 40 mmHg; decrease from Baseline (low) if decreased by >=30 mmHg. For DBP, increase from Baseline (high) if increased by >=30 mmHg; decrease from Baseline (low) if decreased by >=20 mmHg. For HR, increase from Baseline (high) if increased by >=30 bpm; decrease from Baseline (low) if decreased by >=30 bpm. For weight, increase from Baseline (high) if increased by >=7%; decrease from Baseline (low) if decreased by >=7%. Baseline was defined as value at W0. (NCT00428090)
Timeframe: Up to W24
Intervention | Participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
SBP, >140 or <90 | SBP, Increase from Baseline >=40 | SBP, Decrease from Baseline >=30 | DBP, >90 or <50 | DBP, Increase from Baseline >=30 | DBP, Decrease from Baseline >=20 | HR, >100 or <50 | HR, Increase from Baseline >=30 | HR, Decrease from Baseline >=30 | Weight, Increase from Baseline >=7% | Weight, Decrease from Baseline >=7% | |
Donepezil 10 mg | 24 | 3 | 6 | 8 | 1 | 8 | 2 | 1 | 1 | 1 | 5 |
Placebo | 52 | 1 | 7 | 17 | 4 | 8 | 2 | 1 | 3 | 9 | 7 |
RSG XR 2 mg | 61 | 3 | 9 | 16 | 1 | 12 | 4 | 3 | 0 | 21 | 4 |
RSG XR 8 mg | 41 | 3 | 15 | 13 | 1 | 25 | 4 | 3 | 0 | 25 | 3 |
The RUD instrument was developed as a comprehensive tool to assess the amount of resource use among demented par. RUD assess both formal and informal resource use of the par. and the primary caregiver, making it possible to calculate costs from a societal perspective. Q1 relates to assisting par. with basic activities of daily living and Q2 relates to instrumental activities of daily living. The assessments was performed at Baseline, W12 and W24. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at W0. Endpoint treatment differences which were adjusted to take account of missing data are derived. (NCT00428090)
Timeframe: Baseline (W0) and up to W24
Intervention | Hours (Mean) | |||
---|---|---|---|---|
RUD Q1, W12, n=141, 149, 137, 69 | RUD Q1, W24, n=128, 133, 127, 55 | RUD Q2, W12, n=141, 149, 137, 62 | RUD Q2, W24, n=128, 133, 127, 55 | |
Donepezil 10 mg | -5.7 | 3.7 | -5.3 | 1.1 |
Placebo | 2.3 | 19.4 | 13.7 | 17.1 |
RSG XR 2 mg | 4.5 | -0.6 | 9.0 | 9.7 |
RSG XR 8 mg | -9.8 | -2.7 | 4.9 | 11.6 |
Edema was considered as adverse event of special interest (AESI). The process for AESI selection was based on RSG's pharmacologic class and relevant AEs potentially associated with RSG. Percentage of participants reported with edema as AESI were reported. (NCT00550420)
Timeframe: Up to 82 Weeks
Intervention | Percentage of participants (Number) |
---|---|
RSG XR 8 mg | 13 |
The 11-item ADAS-cog was used to assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores ranged from 0 to 70 with higher scores indicating greater dysfunction. Baseline was referred to Visit 1 (W0)assessments. Change from Baseline was calculated as value at scheduled time point minus Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W24 and W52
Intervention | Score on scale (Mean) | |||||
---|---|---|---|---|---|---|
All subject population, W24 | All subject population, W52 | APOE4, Neg, W24 | APOE4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
RSG XR 8 mg | 1.9 | 2.5 | 2.1 | 3.0 | 1.8 | 1.8 |
BW of participants were recorded as vital sign at each visit. The BW were identified as of potential clinical concern if the vales were increased or decreased from Baseline by >=7%. The Baseline assessments were referred to assessments at Visit 1 (W0). Change from Baseline was measured as the BW at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W4, W8, W12, W16, W24, W36, W52, W64 and Follow-up (W82)
Intervention | Kilograms (kg) (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
BW, W4 | BW, W8 | BW, W12 | BW, W16 | BW, W24 | BW, W36 | BW, W52 | BW, Year 2 W12 | BW, Follow-up | |
RSG XR 8 mg | 0.2 | 0.4 | 0.5 | 0.5 | 0.6 | 0.5 | -0.0 | 0.5 | 0.5 |
The DAD, assessed the ability of a participant to execute basic and instrumental activities of daily living (ADL) and leisure activities. The scale consists of 40 questions assessing basic and instrumental ADLs. This scale assesses a participant's ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item was scored as yes: 1, no: 0 and N/A: not applicable. Higher scores indicate less disability with a score of 100 indicating no disability and 0 indicating no functional ability. The percentage score was calculated as (DAD total score/total number of applicable items) multiplied by 100. The DAD was conducted as an interview with the caregiver and took approximately 20 minutes. Baseline was referred to Visit 1 (W0) assessments. Change from Baseline was calculated as value at scheduled time point minus Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W24 and W52
Intervention | Score on scale (Mean) | |||||
---|---|---|---|---|---|---|
All subject population, W24 | All subject population, W52 | APOEe4, Neg, W24 | APOEe4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
RSG XR 8 mg | -3.2 | -5.2 | -4.5 | -6.2 | -2.2 | -3.8 |
HbA1c was evaluated as safety parameter in this study. The values of change from Baseline was presented. The Baseline assessments were referred to assessments at Visit 1 (W0). Change from Baseline was measured as the BW at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Vsit 1 W0), W12, W24, W36, W52, W76 and Follow-up (W82)
Intervention | Percent HbA1c (Mean) | |||||
---|---|---|---|---|---|---|
W12 | W24 | W36 | W52 | W76 | Follow-up | |
RSG XR 8 mg | -0.02 | 0.08 | 0.03 | 0.09 | 0.08 | 0.07 |
HR of participants was recorded as vital sign at each visit. The HR values were identified as of potential clinical concern if the vales were out of the reference range 50 to 100 beats per minute (BPM) or meet a change from Baseline criterion. The change from Baseline criterion was as, increase in HR (high) from Baseline if HR was increased by >= 30 bpm or decrease in HR (Low) from Baseline if HR was decreased by >= 30 bpm from Baseline. The Baseline assessments were referred to assessments at Visit 1 (W 0). Change from Baseline was measured as the HR at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W4, W8, W12, W16, W24, W36, W52, W64 and Follow-up (W82)
Intervention | BPM (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
HR, W4 | HR, W8 | HR, W12 | HR, W16 | HR, W24 | HR, W36 | HR, W52 | HR, Year 2 W12 | HR, Follow-up | |
RSG XR 8mg | 1.1 | 1.8 | 2.2 | 1.2 | 1.0 | 1.7 | -0.8 | 2.9 | 1.6 |
The MMSE consisted of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. The scale was completed by the investigator, based on the performance of the participant, and took approximately 5 to 10 minutes to administer. Change from parent Baseline in MMSE was analyzed using a mixed model for repeated measures (MMRM). Baseline was referred to Visit 1 (W0)assessments. Change from Baseline was calculated as value at scheduled time point minus Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W 24 and W52
Intervention | Score on scale (Mean) | |||||
---|---|---|---|---|---|---|
All subject population, W24 | All subject population, W52 | APOEe4, Neg, W24 | APOEe4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
RSG XR 8 mg | -0.7 | -1.6 | -0.7 | -1.2 | -0.7 | -2.1 |
"The NPI assessed behavioural disturbances comprises 10 dimensions: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressiveness and agitation, irritability, anxiety and aberrant motor activity. The participant caregiver asked about behaviour in the participant. If Yes, the informant then rates both the severity on a 3-point scale, 1: mild to 3: severe (total range: 0-36) and the frequency using a 4-point scale, 1: occasionally to 4: very frequently. The total domain score was frequency × severity. The distress was scored on 5-point scale, 0: no distress to 5 - very severe or extreme. A total NPI score was calculated by adding all domain scores together: NPI total score (from 0-144) and NPI distress score (from 0-60), with higher scores indicating more severe behavioral disturbance. Baseline was referred to Visit 1 (W0) assessments. Change from Baseline was calculated as value at scheduled time point minus Baseline value." (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W24 and W52
Intervention | Score on scale (Mean) | |||||
---|---|---|---|---|---|---|
All subject population, W24 | All subject population, W52 | APOEe4, Neg, W24 | APOEe4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
RSG XR 8 mg | 1.1 | 2.1 | 1.9 | 1.5 | 0.4 | 2.8 |
Non-fasting measures of lipid metabolism including cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TG) were measured at Baseline (W0), W4, W16, W36, W52, Year 2 W24 and Follow-up. The Baseline assessments were referred to assessments at Visit 1 (W0). Change from Baseline was calculated as the value at the indicated visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W4, W16, W36, W52, W76, and W82
Intervention | Millimoles per litre (Mean) | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TC, W4 | TC, W16 | TC, W36 | TC, W52 | TC, Year 2 W24 | TC, Follow-up | HDL, W4 | HDL, W16 | HDL, W36 | HDL, W52 | HDL, Year 2 W24 | HDL, Follow-up | LDL, W4 | LDL, W16 | LDL, W36 | LDL, W52 | LDL, Year 2 W24 | LDL, Follow-up | TG, W4 | TG, W16 | TG, W36 | TG, W52 | TG, Year 2 W24 | TG, Follow-up | |
RSG XR 8 mg | 0.106 | 0.200 | 0.140 | 0.333 | 1.163 | 0.069 | -0.035 | -0.030 | -0.069 | -0.020 | -0.150 | -0.057 | 0.088 | 0.211 | 0.163 | 0.385 | 1.051 | 0.133 | 0.084 | 0.027 | 0.050 | -0.179 | 0.573 | -0.062 |
SBP and DBP of participant were recorded in sitting posture as vital sign at each visit. The blood pressure (BP) values were identified as of potential clinical concern if the vales were out of the reference range (for SBP, 90 to 140 mmHg and DBP, 50 to 90 mmHg) or meet a change from Baseline criterion. The change from Baseline criterion for SBP, was increase from Baseline (high) if increased by more than or equal to (>=) 40 mmHg from Baseline; decrease from Baseline (low) if decreased by >= 30 mmHg from Baseline. For DBP, increase form Baseline (high) if increased by >= 30 mmHg from Baseline; decrease from Baseline (low) if decreased by >= 20 mmHg from Baseline. The Baseline assessments were referred to assessments at Visit 1 (W 0). Change from Baseline was measured as the blood pressure value recorded at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W4, W8, W12, W16, W24, W36, W52, W64 and Follow-up (W82)
Intervention | millimeter of mercury (mmHg) (Mean) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SBP, W4 | SBP, W8 | SBP, W12 | SBP, W16 | SBP, W24 | SBP, W36 | SBP, W52 | SBP, Year 2 W12 | SBP, Follow-up | DBP, W4 | DBP, W8 | DBP, W12 | DBP, W16 | DBP, W24 | DBP, W36 | DBP, W52 | DBP, Year 2 W12 | DBP, Follow-up | |
RSG XR 8 mg | -0.2 | -1.1 | -0.7 | -1.3 | -1.2 | -3.0 | 0.3 | -0.1 | -0.5 | -0.8 | -2.1 | -2.0 | -2.2 | -2.1 | -3.0 | -1.4 | 2.8 | -0.9 |
The CIBIC+ score used for global functioning assessment. The CIBIC+ assessment comprised of a 7-point rating of severity. It was rated on a scale of 1 to 7 as 1: markedly improved, 2.: moderately improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: moderately worse and 7: markedly worse; The lower score indicated betterment in functioning and higher score means greater dysfunction. The scale was based on interviews with the participant and the caregiver and was completed by an independent rater. (NCT00550420)
Timeframe: Baseline (Visit 1, W0), W 24 and W 52
Intervention | Score on scale (Mean) | |||||
---|---|---|---|---|---|---|
All subject population, W24 | All subject population, W52 | APOEe4, Neg, W24 | APOEe4, Neg, W52 | APOEe4, Pos, W24 | APOEe4, Pos, W52 | |
RSG XR 8 mg | 4.3 | 4.5 | 4.3 | 4.7 | 4.3 | 4.3 |
BW of participants were recorded as vital sign at each visit. The BW were identified as of potential clinical concern if the vales were increased or decreased from Baseline by >=7%. The Baseline assessments were referred to assessments at Visit 1 (W0). Change from Baseline in BW was measured as the BW value at specified visit minus the Baseline BW value. Number of participants with abnormal BW at any time during treatment period were reported. (NCT00550420)
Timeframe: Baseline (Visit 1, W0) to W 52
Intervention | Participants (Count of Participants) | |
---|---|---|
Increase from Baseline >=7% | Decrease from Baseline >=7% | |
RSG XR 8 mg | 30 | 16 |
HR of participants was recorded as vital sign at each visit. The HR values were identified as of potential clinical concern if the vales were out of the reference range 50 to 100 beats per minute (BPM) or meet a change from Baseline criterion. The change from Baseline criterion was as, increase in HR (high) from Baseline if HR was increased by >= 30 bpm or decrease in HR (Low) from Baseline if HR was decreased by >= 30 bpm from Baseline. The Baseline assessments were referred to assessments at Visit 1 (W 0). Change from Baseline was measured as the HR at specified visit minus the Baseline value. Number of participants with abnormal HR at any time during treatment period were reported. (NCT00550420)
Timeframe: Up to 82 weeks
Intervention | Participants (Count of Participants) | |
---|---|---|
HR, >100 or <50 | HR, Increase from baseline >=30 | |
RSG XR 8 mg | 3 | 2 |
SBP and DBP of participant were recorded in sitting posture as vital sign at each visit. The blood pressure (BP) values were identified as of potential clinical concern if the vales were out of the reference range (for SBP, 90 to 140 mmHg and DBP, 50 to 90 mmHg) or meet a change from Baseline criterion. The change from Baseline criterion for SBP, was increase from Baseline (high) if increased by more than or equal to (>=) 40 mmHg from Baseline; decrease from Baseline (low) if decreased by >= 30 mmHg from Baseline. For DBP, increase form Baseline (high) if increased by >= 30 mmHg from Baseline; decrease from Baseline (low) if decreased by >= 20 mmHg from Baseline. The Baseline assessments were referred to assessments at Visit 1 (W 0). Change from Baseline was measured as the blood pressure value recorded at specified visit minus the Baseline value. (NCT00550420)
Timeframe: Up to 82 weeks
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
SBP, >140 or <90, | SBP, Increase from Baseline >=40, | SBP, Decrease from Baseline >=30, | DBP, >90 or <50, | DBP, Increase from Baseline >=30, | DBP, Decrease from Baseline >=20, | |
RSG XR 8 mg | 84 | 8 | 22 | 23 | 2 | 31 |
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The drug related-AEs of special interest (AESI) was reported. The severity of the AESI was categorized as mild, moderate and severe. Number of participants with AEs were reported for treatment duration of the study. (NCT00550420)
Timeframe: Up to Week 82
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Any AEs | Total Drug-Related AESI | Mild AESI | Moderate AESI | Severe AESI | |
RSG XR 8mg | 125 | 46 | 31 | 13 | 2 |
The clinical chemistry parameters including alanine amino transferase (ALT), aldolase, aspartate amino transferase (AST), blood urea nitrogen /creatinine (BUN/Creat) ratio, cholesterol (Chol), creatine kinase, creatinine, direct bilirubin, gamma glutamyl transferase (GGT), glucose, high density lipid (HDL), low density lipid (LDL), potassium, troponin 1, and urea were assessed as safety parameters. The number of participants with values outside the reference range (potential clinical concern ) at any time on treatment (ATOT) and follow-up period were reported. The treatment period was till W104 followed by 6 weeks of follow-up period till W110 of study. (NCT00550420)
Timeframe: Up to 82 weeks
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALT, ATOT, High | ALT, Follow-up, High | Aldolase, ATOT, High | Aldolase, ATOT, Low | Aldolase, Follow-up, Low | AST, ATOT, High | AST, Follow-up, High | BUN/Creat ratio, ATOT, High | BUN/Creat ratio, Follow-up, High | Chol, ATOT, High | Chol, Follow-up, High | Creatine Kinase, ATOT, High | Creatine Kinase, Follow-up, High | Creatinin, ATOT, High | Creatinin, Follow-up, High | Direct Bilirubin, ATOT, High | GGT, ATOT, High | GGT, Follow-up, High | Glucose, ATOT, High | Glucose, ATOT, Low | Glucose, Follow-up, High | HDL, ATOT, Low | LDL, ATOT, High | LDL, Follow-up, High | Potassium, ATOT, High | Potassium, ATOT, Low | Troponin I, ATOT, High | Urea, ATOT, High | Urea, Follow-up, High | |
RSG XR 8 mg | 1 | 1 | 3 | 7 | 3 | 2 | 1 | 18 | 1 | 52 | 13 | 32 | 7 | 4 | 5 | 1 | 308 | 142 | 19 | 5 | 8 | 1 | 135 | 45 | 4 | 1 | 2 | 19 | 7 |
The hematological parameters including eosinophils, lymphocytes, monocytes, platelet count, Segmented Neutrophils, total neutrophils, white blood cell (WBC), red blood cell (RBC) counts, hemoglobin, hematocrit count, mean corpuscle hemoglobin (MCH) and mean corpuscle volume (MCV) were analyzed as safety parameters. The number of participants with values outside the reference range (potential clinical concern ) at any time on treatment (ATOT) and follow-up period were reported. The treatment period was till W104 followed by 6 weeks of follow-up period till W110 of study. (NCT00550420)
Timeframe: Up to 82 weeks
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eosinophils, ATOT, High | Hematocrit, ATOT, Low | Hematocrit, Follow-up, Low | Hemoglobin, ATOT, High | Hemoglobin, ATOT, Low | Hemoglobin, Follow-Up, Low | Lymphocytes, ATOT, Low | Lymphocytes, Follow-Up, Low | MCH, ATOT, High | MCH, Follow-Up, High | MCV, ATOT, High | MCV, Follow-Up, High | Monocytes, ATOT, Low | Monocytes, ATOT, High | Platelet count, ATOT, High | Platelet count, ATOT, Low | Red Cell Distribution Width, ATOT, High | Red Cell Distribution Width,Follow-up, High | Red Blood Cell count, ATOT, Low | Red Blood Cell count, Follow-up, Low | Segmented Neutrophils, ATOT, High | Segmented Neutrophils, ATOT, Low | Segmented Neutrophils, Follow-up, Low | Total Neutrophils, ATOT, High | Total Neutrophils, ATOT, Low | Total Neutrophils, Follow-Up, Low | WBC, ATOT, Low | |
RSG XR 8 mg | 1 | 2 | 1 | 1 | 20 | 8 | 5 | 3 | 1 | 1 | 1 | 1 | 17 | 5 | 1 | 2 | 30 | 8 | 4 | 4 | 1 | 14 | 2 | 1 | 14 | 2 | 9 |
A serious adverse event is defined as any untoward medical occurrence that, at any dose results in death, life-threatening condition, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or a congenital anomaly or birth defect. The SAEs and deaths are reported from Visit 1 (W0) till end of the follow-up period (W110) (NCT00550420)
Timeframe: Up to Week 82
Intervention | Participants (Count of Participants) | |
---|---|---|
Any SAE | Death | |
RSG XR 8 mg | 8 | 3 |
2 reviews available for donepezil and Adverse Drug Event
Article | Year |
---|---|
A Novel Formulation: Donepezil Patch.
Topics: Acetylcholinesterase; Donepezil; Drug-Related Side Effects and Adverse Reactions; Humans; Rivastigmi | 2023 |
Pain and palliative care pharmacotherapy literature summaries and analyses.
Topics: Alzheimer Disease; Amphetamines; Anesthetics, Local; Anticoagulants; Antidepressive Agents; Depressi | 2009 |
2 trials available for donepezil and Adverse Drug Event
Article | Year |
---|---|
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Costs; Drug-R | 2017 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; D | 2010 |
8 other studies available for donepezil and Adverse Drug Event
Article | Year |
---|---|
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database.
Topics: Acetylcholinesterase; Cholinesterase Inhibitors; Donepezil; Drug-Related Side Effects and Adverse Re | 2023 |
Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug-Related Side Effect | 2020 |
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase | 2015 |
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
Topics: Acetamides; Advertising; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antivira | 2003 |